Electronic Acknowledgement Receipt				
EFS ID:	2623353			
Application Number:	10750005			
International Application Number:				
Confirmation Number:	9934			
Title of Invention:	Methods for reducing oxidative stress in a cell with a sulfhydryl protected glutathione prodrug			
First Named Inventor/Applicant Name:	Herbert T. Nagasawa			
Correspondence Address:	MANDEL & ADRIANO - SUITE 203 572 EAST GREEN STREET PASADENA CA 91101 US 626 395 7801 -			
Filer:	Nan Wu./Marta Vanegas			
Filer Authorized By:	Nan Wu.			
Attorney Docket Number:	30451.2USU1			
Receipt Date:	20-DEC-2007			
Filing Date:	30-DEC-2003			
Time Stamp:	15:40:39			
Application Type:	Utility under 35 USC 111(a)			
Payment information:				
Submitted with Payment	yes			

\$635

Deposit Account

Payment Type

Payment was successfully received in RAM

RAM confirmation Number			1172			
Deposit Account		501283	501283			
Authorized U						
The Director	of the USPTO is hereby authorized t	to charge indicated fees and	credit any overpaym	ent as follow	vs:	
Charge	any Additional Fees required under 37	C.F.R. Section 1.16 (National a	pplication filing, search,	and examina	ation fees	
Charge	any Additional Fees required under 37	C.F.R. Section 1.17 (Patent app	olication and reexamina	tion processi	ng fees)	
Charge	any Additional Fees required under 37	C.F.R. Section 1.19 (Document	supply fees)			
Charge	any Additional Fees required under 37	C.F.R. Section 1.20 (Post Issua	ince fees)			
Charge	any Additional Fees required under 37	C E D. Saction 1 21 (Miscallane	oue fees and charges)			
		C.F.N. Section 1.21 (Miscellane	eous rees and charges)			
File Listin	ıg:					
Document Number	Document Description	File Name	File Size(Bytes) /Message Digest	Multi Part /.zip	Page: (if app	
Number			718136	T dit /.zip	(п арр	
1	Request for Continued Examination (RCE)	CELG00301US-RCE.pdf		no	3	
			f1a2c0213414d87832f9ff546f02cec466 ed3c06			
Warnings:						
Information:						
2		CELG00301US-Response.p	261643	yes	8	
		df	c3c257ee7c5d93c325ecb993a448a43b 769bc02a			
	Multipa	rt Description/PDF files in				
1	Document Description  Amendment Submitted/Entered with Filling of CPA/RCE		Start	End		
1			Otan			
- 1			1 1	1		
-				+		
	Claims	2	5			
	Applicant Arguments/Remarks Made in an Amendment		6	8		
Warnings:			'			
Information:						
3	Fee Worksheet (PTO-06)	fee-info.pdf	8356	no	2	
			ceedb4c90d82d80c974b13b831e9ed2c			
			ceedb4c90d82d80c974bf3b831e9ed2c 38197c55			
Mornings:						
Warnings:						

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

## New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 566), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

## National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/IDO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filling Receipt, in due course.

## New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.